Codiak BioSciences, Inc. Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 56 rows, 56 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-02-16: Reporting owner Bain Linda; Form 4; Security Restricted Stock Units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2023-02-16: Reporting owner WILLIAMS DOUGLAS E; Form 4; Security Restricted Stock Units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2023-02-16: Reporting owner Konstantinov Konstantin; Form 4; Security Restricted Stock Units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2023-02-16: Reporting owner Bernstein Karen; Form 4; Security Restricted Stock Units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-02-16 | Bain Linda Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,613 15,224 owned after | $0.00 | 2023-02-21 | |
| 2023-02-16 | WILLIAMS DOUGLAS E Director, Officer (President & CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −22,969 45,937 owned after | $0.00 | 2023-02-21 | |
| 2023-02-16 | Konstantinov Konstantin Officer (Chief Technology Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,200 8,400 owned after | $0.00 | 2023-02-21 | |
| 2023-02-16 | Bernstein Karen Director | 4 | Restricted Stock Units Derivative · Indirect · See footnote | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,750 0 owned after | $0.00 | 2023-02-21 | |
| 2023-02-16 | Haddock Jason Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,750 0 owned after | $0.00 | 2023-02-21 | |
| 2023-02-16 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,350 14,700 owned after | $0.00 | 2023-02-21 | |
| 2023-02-16 | GILLIS STEVEN Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,750 0 owned after | $0.00 | 2023-02-21 | |
| 2023-02-16 | COONEY CHARLES L Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,750 0 owned after | $0.00 | 2023-02-21 | |
| 2023-02-16 | Barna Nicole Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,150 6,300 owned after | $0.00 | 2023-02-21 | |
| 2023-02-16 | Howze Yalonda Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,856 9,712 owned after | $0.00 | 2023-02-21 | |
| 2023-02-16 | MELAS KYRIAZI THEO Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,750 0 owned after | $0.00 | 2023-02-21 | |
| 2023-01-19 | Bain Linda Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 10,000 owned after | $0.00 | 2023-01-23 | |
| 2023-01-19 | Konstantinov Konstantin Officer (Chief Technology Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,800 5,600 owned after | $0.00 | 2023-01-23 | |
| 2023-01-19 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,834 5,666 owned after | $0.00 | 2023-01-23 | |
| 2023-01-19 | WILLIAMS DOUGLAS E Director, Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,667 27,333 owned after | $0.00 | 2023-01-23 | |
| 2023-01-19 | Howze Yalonda Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,000 8,000 owned after | $0.00 | 2023-01-23 | |
| 2023-01-19 | Barna Nicole Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,167 4,333 owned after | $0.00 | 2023-01-23 | |
| 2022-09-16 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $0.00 | 2022-09-20 | |
| 2022-09-16 | Bain Linda Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $0.00 | 2022-09-20 | |
| 2022-09-16 | Mauro David J Officer (Chief Medical Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $0.00 | 2022-09-20 | |
| 2022-09-16 | Konstantinov Konstantin Officer (Chief Technology Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $0.00 | 2022-09-20 | |
| 2022-09-16 | Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $0.00 | 2022-09-20 | |
| 2022-09-16 | Howze Yalonda Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $0.00 | 2022-09-20 | |
| 2022-08-16 | Bain Linda Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,613 22,837 owned after | $0.00 | 2023-02-21 | |
| 2022-08-16 | WILLIAMS DOUGLAS E Director, Officer (President & CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −22,969 68,906 owned after | $0.00 | 2023-02-21 | |
| 2022-08-16 | Konstantinov Konstantin Officer (Chief Technology Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,200 12,600 owned after | $0.00 | 2023-02-21 | |
| 2022-08-16 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,350 22,050 owned after | $0.00 | 2023-02-21 | |
| 2022-08-16 | Barna Nicole Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,150 9,450 owned after | $0.00 | 2023-02-21 | |
| 2022-08-16 | Howze Yalonda Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,857 14,568 owned after | $0.00 | 2023-02-21 | |
| 2022-06-17 | Haddock Jason Director | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,500 1,500 owned after | $0.00 | 2022-06-21 | |
| 2022-06-17 | Bernstein Karen Director | 4 | Restricted Stock Units Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,500 1,500 owned after | $0.00 | 2022-06-21 | |
| 2022-06-17 | Eggimann Anne-Virginie Director | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,500 1,500 owned after | $0.00 | 2022-06-21 | |
| 2022-06-17 | MELAS KYRIAZI THEO Director | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,500 1,500 owned after | $0.00 | 2022-06-21 | |
| 2022-06-17 | COONEY CHARLES L Director | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,500 1,500 owned after | $0.00 | 2022-06-21 | |
| 2022-06-17 | GILLIS STEVEN Director | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,500 1,500 owned after | $0.00 | 2022-06-21 | |
| 2022-06-17 | Pandite Arundathy N. Director | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,500 1,500 owned after | $0.00 | 2022-06-21 | |
| 2022-05-02 | Mauro David J Officer (Chief Medical Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $0.00 | 2022-05-04 | |
| 2022-02-16 | Bernstein Karen Director | 4 | Restricted Stock Units Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,750 8,750 owned after | $0.00 | 2022-02-18 | |
| 2022-02-16 | GILLIS STEVEN Director | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,750 8,750 owned after | $0.00 | 2022-02-18 | |
| 2022-02-16 | WILLIAMS DOUGLAS E Director, Officer (President & CEO) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +91,875 91,875 owned after | $0.00 | 2022-02-18 | |
| 2022-02-16 | Brudnick Richard Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,275 16,275 owned after | $0.00 | 2022-02-18 | |
| 2022-02-16 | Bain Linda Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,450 30,450 owned after | $0.00 | 2022-02-18 | |
| 2022-02-16 | Howze Yalonda Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,425 19,425 owned after | $0.00 | 2022-02-18 | |
| 2022-02-16 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,400 29,400 owned after | $0.00 | 2022-02-18 | |
| 2022-02-16 | COONEY CHARLES L Director | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,750 8,750 owned after | $0.00 | 2022-02-18 | |
| 2022-02-16 | MELAS KYRIAZI THEO Director | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,750 8,750 owned after | $0.00 | 2022-02-18 | |
| 2022-02-16 | Konstantinov Konstantin Officer (Chief Technology Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,800 16,800 owned after | $0.00 | 2022-02-18 | |
| 2022-02-16 | Haddock Jason Director | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,750 8,750 owned after | $0.00 | 2022-02-18 | |
| 2022-02-16 | Barna Nicole Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,600 12,600 owned after | $0.00 | 2022-02-18 | |
| 2022-01-19 | Brudnick Richard Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,400 8,400 owned after | $0.00 | 2022-01-21 | |
| 2022-01-19 | Howze Yalonda Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $0.00 | 2022-01-21 | |
| 2022-01-19 | WILLIAMS DOUGLAS E Officer (President & CEO) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,000 41,000 owned after | $0.00 | 2022-01-21 | |
| 2022-01-19 | Barna Nicole Officer (See Remarks) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,500 6,500 owned after | $0.00 | 2022-01-21 | |
| 2022-01-19 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,500 8,500 owned after | $0.00 | 2022-01-21 | |
| 2022-01-19 | Konstantinov Konstantin Officer (Chief Technology Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,400 8,400 owned after | $0.00 | 2022-01-21 | |
| 2022-01-19 | Bain Linda Officer (Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $0.00 | 2022-01-21 |